Charles Link
Company: Syncromune
Job title: Chief Medical Officer
Seminars:
Proving the Clinical Efficacy of SV-102 in Multiple Cancer Indications 1:00 pm
Transforming the personalized cancer space by freezing tumors in situ, lysing and releasing the neoantigens to activate T cells Employing a two-pronged attack with a cocktail of checkpoint inhibitors in the same local environment for maximum patient effect Demonstrating the viability of this personalized cancer therapy in metastatic prostate cancer and beyondRead more
day: Conference Day Two